Update:

The recent price hike of the EpiPen has got many people feeling very uneasy.  It is hard to grasp why a company would dramatically increase the price of something that is so critical to so many people.  People need their EpiPens in order to live and for many people the recent cost increase of this medicine is unbearable.

Here is a statement from the American College of Allergy, Asthma and Immunology:

"The American College of Allergy, Asthma and Immunology (ACAAI) represents more than 6,000 allergists-immunologists and allied health professionals. Our members live and practice throughout the United States, and treat patients with severe allergies that cause anaphylaxis. The top priority of our members is to make sure that every patient needing an epinephrine auto-injector has access to the life-saving medicine. ACAAI always has and always will advocate for affordable medicine for the patients we serve.

Allergists do not set prices for medication, but as an advocacy organization, we work to ensure that patients get the necessary epinephrine supplies to keep them safe in an emergency. We encourage all patients with difficulty affording their allergy medications to discuss ways of obtaining them with their allergist. Anyone who has severe allergies and requires epinephrine should be under the care of an allergist. ACAAI supports continuing the ongoing dialogue between patients, advocacy groups, physician groups, the US Congress, and the pharmaceutical industry to help solve this complicated problem."

We understand your frustration and we are hopeful that something will be done about this issue.  Dr. Steven and Dr. Bukstein do their best to work with each patient - helping you to understand the pros and cons of alternative medication and make you aware of coupons and discounts.  If you would like to speak to someone from the Allergy, Asthma & Sinus Center about your medication options, please give us a call at (414) 529-8500 and we would be happy to help.

Recent Articles:

New York Times - Mylan to Offer Generic EpiPen at Half the Price

Mylan - Taking Immediate Action to Further Enhance Access to EpiPen